[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
[2] Lee A, Ng W, Chan L, Hung W, Chan C, Sze H, et al. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;110:377-84.
[3] Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998.
[4] Wee J, Tan E, Tai B, Wong H, Leong S, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23:6730-8.
[5] Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, et al. Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio. Int J Radiat Oncol Biol Phys. 2018;101:1078-86.
[6] Lee A, Tung S, Chan A, Chappell R, Fu Y, Lu T, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2011;98:15-22.
[7] Chen Y, Sun Y, Liang S, Zong J, Li W, Chen M, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013;119:2230-8.
[8] Hui E, Ma B, Leung S, King A, Mo F, Kam M, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27:242-9.
[9] Hong R, Hsiao C, Ting L, Ko J, Wang C, Chang J, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29:1972-9.
[10] Sun Y, Li W, Chen N, Zhang N, Hu G, Xie F, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. The Lancet Oncology. 2016;17:1509-20.
[11] Cao S, Yang Q, Guo L, Mai H, Mo H, Cao K, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. European journal of cancer (Oxford, England : 1990). 2017;75:14-23.
[12] Lee AWM, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017;123:4147-57.
[13] Chan A, Leung S, Ngan R, Teo P, Lau W, Kwan W, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer I. 2005;97:536-9.
[14] Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29:731-6.
[15] Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020;18:873-98.
[16] Azen R, Traxel N. Using Dominance Analysis to Determine Predictor Importance in Logistic Regression. Journal of Educational and Behavioral Statistics. 2009;34:319-47.
[17] Dutz A, Lock S. Competing risks in survival data analysis. Radiother Oncol. 2019;130:185-9.
[18] Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in Medicine. 2015;34:3661-79.
[19] Chen Y, Tang L, Yang Q, Poh S, Hui E, Chan A, et al. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24:1824-33.
[20] Ribassin-Majed L, Marguet S, Lee A, Ng W, Ma J, Chan A, et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35:498-505.
[21] Chen Y, Wang Z, Chen L, Liu X, Tang L, Mao Y, et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26:205-11.
[22] Blanchard P, Lee A, Marguet S, Leclercq J, Ng W, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. The Lancet Oncology. 2015;16:645-55.
[23] Lee AW, Tung SY, Ngan RK, Chappell R, Chua DT, Lu TX, et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer. 2011;47:656-66.
[24] Lee A, Tung S, Chua D, Ngan R, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer I. 2010;102:1188-98.
[25] Chen C, Lu TX, Zhao C, Sun Y, Lu LX, Han F, et al. Analysis of the effect of T3-4N0-3 stage nasopharyngeal carcinoma with radiotherapy alone. Int J Radiat Oncol. 2006;66:S457-S.
[26] Sun XS, Chen WH, Liu SL, Liang YJ, Chen QY, Guo SS, et al. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort. Cancer Med. 2019;8:4214-25.
[27] Sun XS, Li XY, Xiao BB, Liu SL, Chen QY, Tang LQ, et al. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up. Oral Oncol. 2020;100:104490.
[28] Cheng S, Tsai S, Yen K, Jian J, Feng A, Chan K, et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. International journal of radiation oncology, biology, physics. 2005;61:456-65.
[29] Wang X, Hu C, Ying H, He X, Zhu G, Kong L, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the 2013 updated consensus guidelines for neck node levels. Radiother Oncol. 2015;115:41-5.
[30] Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER Treatment Data With Medicare Claims. Med Care. 2016;54:e55-64.